See the DrugPatentWatch profile for Spravato
Spravato, known by its generic name esketamine, is a nasal spray used for treatment-resistant depression and depressive symptoms in adults with major depressive disorder [1].
What is the difference between Spravato and esketamine?
Spravato is the brand name for esketamine, a medication developed by Janssen Pharmaceuticals [1][2]. Esketamine is the active pharmaceutical ingredient in Spravato [1].
When is Spravato expected to become available as a generic?
The patent for Spravato is set to expire in November 2029 [3]. This indicates that a generic version of esketamine could become available around that time, assuming no further patent extensions or successful legal challenges [3].
Who manufactures generic Spravato?
Currently, Spravato is manufactured by Janssen Pharmaceuticals [2]. Once patents expire, other pharmaceutical companies may seek approval to produce and market generic versions of esketamine [3].
What is the mechanism of action for esketamine?
Esketamine works differently than traditional antidepressants. It is an NMDA receptor antagonist, which is thought to help rapidly restore synaptic connections in certain brain circuits, leading to a faster onset of antidepressant effects [1][4].
What are the potential risks and side effects of Spravato?
Spravato carries a Risk Evaluation and Mitigation Strategy (REMS) due to potential for serious adverse outcomes. These include sedation, dissociation, and abuse and misuse [1]. Patients must be monitored for at least two hours after administration. Common side effects can include nausea, dizziness, and vertigo [1].
What is the clinical data supporting Spravato's efficacy?
Clinical trials have demonstrated Spravato's efficacy in reducing depressive symptoms in treatment-resistant depression [4]. It has shown rapid antidepressant effects in some patients [4].
How does Spravato compare to other depression treatments?
Spravato offers a different mechanism of action compared to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), which are more common first-line treatments [4]. Its rapid action is a key differentiator for patients who have not responded to other therapies [4].
What is the cost of Spravato?
The cost of Spravato can be significant, and it is often covered by insurance, though patient co-pays may vary [1]. Generic versions, when available, are typically less expensive than their brand-name counterparts.
Are there ongoing legal challenges or patent expirations affecting Spravato?
DrugPatentWatch.com lists the patent expiration for Spravato as November 13, 2029 [3]. This is a key date for the potential market entry of generic esketamine.
What are patient concerns regarding Spravato?
Patients may have concerns about the administration process, the required monitoring period, potential side effects like dissociation and sedation, and the overall cost of treatment [1]. The unique delivery method and monitoring requirements are significant considerations.
Sources:
[1] https://www.spravato.com/
[2] https://www.janssen.com/
[3] https://drugpatentwatch.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999734/